alexa New Anticoagulation Medications for Atrials Fibrillation

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

New Anticoagulation Medications for Atrials Fibrillation

 In December 2012, the Food and Drug Administration approves apixaban for reducing risks of stroke and venous thromboembolism in patients with nonvalvular atrial fibrillation (NAF) [1]. Apixaban is the third new oral anticoagulation agent that came into the market [1-3]. Prior to the approval of apixaban, dabigatran (a direct thrombin inhibitor) was approved in 2010, and rivaroxaban (a factor Xa inhibitor) was approved in November 2011. All of these agents have been compared to warfarin in various landmark trials

Citation: Wang A, Nguyen T (2013) New Anticoagulation Medications for Atrials Fibrillation. J Develop Drugs 2:e123. doi: 10.4172/2329-6631.1000e123

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger